Imcheck Therapeutics is a biotechnology company developing ICT41, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9Vδ2 T cells to combat infectious diseases.

Imcheck Therapeutics

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.

Adocia SA

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. 

As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. 

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.  

Bpifrance

Kurma Partners

EQT life science

Idinvest Partners

Wellington Partners

Pfizer Venture Investments

Kinled Holding

Boehringer Ingelheim Venture Fund

Agent Capital

Alexandria Venture Investments

Gimv

Pureos Bioventures

Earlybird Venture Capital

Leukemia & Lymphoma Society

Eurazeo

Invus

ImCheck Therapeutics

Today, on International Women's Day, ImCheck Therapeutics proudly stands with women everywhere, celebrating the remarkable resilience of the women who drive innovation and progress within our organization. 
To the women on our team. Your talent, dedication and fearlessness are the driving force behind our success. We applaud your courage and commitment to excellence.
To our women leaders. Thank you for paving the way and inspiring the next generation of talent with grace. Your vision and determination are invaluable assets to our company.
On this special day, let's continue to champion equality and diversity in the workplace and recognize the collective strength that propels us forward.
 
Together, we can create a more inclusive and empowering environment for all!

In celebration of the 9th International Day of Women and Girls in Science, we salute and celebrate an oustanding team of women who have acted and continue to act as agents of change to accelerate innovation, development and change in our organization. 

Your contributions have shaped this company and we commend your courage, talent and fearlessness. 

To our leaders, we salute you for charting the course, for being trailblazers and for showing our junior employees that they too can pursue their dreams.  

From all of us at ImCheck... Thank You ! 

Metric
Company Name	Imcheck Therapeutics	Adocia SA	Biotech 365	Neovacs S.A.
Symbol		ADOC		ALNEV
MSH ID	COM:IMCHECKTHERAPEUTICS	COM:ADOCIA	COM:BIOTECH-365	COM:NEOVACS
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Financial Services & Finance	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology Business Services	Biotechnology
Country	FR	FR	FR	FR
Stage		Post-IPO Debt		Post-IPO Debt
Employee Count	51	78		22
Website	imchecktherapeutics.com	adocia.com	biotech-365.com	neovacs.com
LinkedIn	imcheck-therapeutics	adocia		neovacs
Founders

Metric
Market Cap	645.43M	100.30M		52.99K
Enterprise Value
Monthly Web Traffic		521	68
Web Traffic Growth		-0.54	-0.57
Valuation
Raised Capital		6.96M		4.77M

Metric
Revenue	2.27M	563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-18.95M	-7.13M
EBITDA	-18.09M	-7.12M
Operating Income	-18.61M	-7.30M
Net Income	-22.35M	-9.24M
EPS	-2.02	-0.00
Diluted EPS	-2.02	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-2.44	-9.71
Operating Profit Margin	-2.49	-12.95
EBITDA Margin	-7.96	-12.64
Net Profit Margin	-2.76	-16.39
Return on Equity	3.60	-0.12
Return on Assets	-1.08	-0.11
Return on Capital Employed	4.03	-0.14

COM:IMCHECKTHERAPEUTICS

Imcheck Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.60
P/B Ratio	-6.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	35.40	5.78
EV Multiple	-2.91	-0.04

Metric
Days Sales Outstanding	275.72
Days Payables Outstanding	745.68	1.22K
Days Inventory Outstanding	9.81
Operating Cycle	823.59	11.67K
Cash Conversion Cycle	776.31	11.39K
Asset Turnover	0.53	0.01

Metric
Operating Cash Flow	-5.23M	-2.02M
Free Cash Flow	-5.39M	-2.24M
Cash Flow to Debt	-0.46	-1.47
Operating Cash Flow/Sales	-1.27	-3.59
Free Cash Flow Yield	-0.11	-0.00

Metric
Cash & Equivalents	13.69M	936.97K
Accounts Receivable	1.23M
Inventory	287.29K
Goodwill
Debt to Capitalization	2.81	0.06
Debt to Assets	1.08	0.02
Current Ratio	1.05	2.32
Quick Ratio	1.01	1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue